TSIs Chinese Ops TGA Approved

MISSOULA, Mont.—TSI Health Sciences’ wholly-owned manufacturing operations, Jiangyin TSI Pharmaceutical Co. Ltd., in Jiangsu, China, was granted approval from Australia’s Therapeutic Goods Administration (TGA) for production of chondroitin sulfate sodium. TGA also verified and approved the company’s TSIYangzhou Natural Products Co. Ltd. for glucosamine production.

“We’re now positioned to compete with the elite on a global basis,” said Larry Kolb, president, U.S. operations. “Being able to pursue drug business as a result of these recent certifications represents huge potential from a business perspective, but it also differentiates our philosophy as an ingredient supplier. The TGA process is among the most stringent in the world. It means we have absolute and total control of our manufacturing processes. It reinforces our USP ingredient certification for chondroitin sulfate, and where consistent supply of highest quality, safe ingredients is an issue, we should be at the table.”

For more information, visit www.tsiinc.com or Booth #1716 at SupplySide East.